Abstract
Considerable effort has led to an increased interest in emerging preclinical and clinical data regarding the pathophysiological changes in the posttraumatic brain. It is widely believed that delayed cell damage and death contributes to behavioral impairment following traumatic brain injury. However, no drug therapy to attenuate this process is available at present, and the development of new therapeutic regimen is urgently warranted. This manuscript represents a compendium of recent preclinical work undertaken to evaluate new pharmacologic strategies in the experimental setting as a first step towards the development of a therapeutic armamentarium directed to improve functional recovery in head-injured patients.
Keywords: Pharmacology therapy, Traumatic brain injury, Cation homeostasis, Glutamate antagonists, Calpain antagonists, Cytoskeleton, Nitric oxide, Nitric oxide synthetase, Free rasical scavengers, Lipid peroxidation
Current Pharmaceutical Design
Title: Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies
Volume: 7 Issue: 15
Author(s): H. L. Laurer and T. K. McIntosh
Affiliation:
Keywords: Pharmacology therapy, Traumatic brain injury, Cation homeostasis, Glutamate antagonists, Calpain antagonists, Cytoskeleton, Nitric oxide, Nitric oxide synthetase, Free rasical scavengers, Lipid peroxidation
Abstract: Considerable effort has led to an increased interest in emerging preclinical and clinical data regarding the pathophysiological changes in the posttraumatic brain. It is widely believed that delayed cell damage and death contributes to behavioral impairment following traumatic brain injury. However, no drug therapy to attenuate this process is available at present, and the development of new therapeutic regimen is urgently warranted. This manuscript represents a compendium of recent preclinical work undertaken to evaluate new pharmacologic strategies in the experimental setting as a first step towards the development of a therapeutic armamentarium directed to improve functional recovery in head-injured patients.
Export Options
About this article
Cite this article as:
Laurer L. H. and McIntosh K. T., Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies, Current Pharmaceutical Design 2001; 7 (15) . https://dx.doi.org/10.2174/1381612013397285
DOI https://dx.doi.org/10.2174/1381612013397285 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways
Current Neurovascular Research Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Blockage of Central Sphingosine-1-phosphate Receptor does not Abolish the Protective Effect of FTY720 in Early Brain Injury after Experimental Subarachnoid Hemorrhage
Current Drug Delivery Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery CYLD-Mediated Signaling and Diseases
Current Drug Targets Activity-Dependent Neurorehabilitation Beyond Physical Trainings: “Mental Exercise” Through Mirror Neuron Activation
CNS & Neurological Disorders - Drug Targets Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Transfersomes: The Ultra-Deformable Carrier System for Non-Invasive Delivery of Drug
Current Drug Delivery Perspectives of Medieval Persian Medicine on Multiple Sclerosis
Current Drug Metabolism The Protective Role of Heme Oxygenase-1 in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Current Chemical Biology